M2Bio Sciences (OTCBB:MRES)

CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, March 15, 2023 /EINPresswire.com/ -- Institute of Biomedical Research (OTC PINK: MRES) ("M2Bio Sciences'' or the "Company"), a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:

Shadrack ‘’Blambee’’ Nsua has joined the growing list of remarkable M2Bio Sciences Brand Ambassadors.

Hailing from the Democratic Republic of Congo, 29-year-old Shadrack “Blambee” Nsua is a Pro MMA fighter out of Port Elizabeth, South Africa and currently the #17th ranked Pro Men's Middleweight in South Africa.

You may have seen his extraordinary win over Mark Kamba at the latest EFC101 by way of Verbal Submission on March 02 2023 at the EFC Peak Performance Institute In Johannesburg, South Africa. His next fight will be at EFC 103 or 104.

Currently 2-0 in the EFC, Shadrack is fighting under PESFA Academy and coach Chris Bright in Port Elizabeth. Coming up from an amateur undefeated record, he looks to build himself in the pro levels and eventually get fights around the world. His dream is to compete with the best in the UFC. As of now he is practicing and perfecting all the fighting disciplines and building his character while managing and running his own fitness apparel and casual wear brand “Blambee Clothing”.

“As a former MMA Amateur Lightweight Champion I know what it takes to win. Hard work, consistency, and so much discipline. I know I’m going to make a mark as a pro MMA fighter as well. My coach Chris is second to none and having the M2Bio Sciences Team behind me is such a big plus.”

‘’Shadrack is technically sound and has incredible hulk-like strength. His latest victory demonstrated just how good he is and how great he will become. Outside the ring, like so many of these great fighters, a gentle giant. We are blessed to have Shadrack on the M2Bio Sciences Team.” said Jeff Robinson, CEO, M2Bio Sciences.

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES".
Publicly traded company (OTC Pink: MRES)

Website: www.m2bio.co
E-mail: info@m2bio.co

Find us on social media
Instagram: m2bio.sciences
Facebook: M2Bio Sciences
LinkedIn: M2Bio Sciences, Inc.

Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

Jeff Robinson
M2Bio Sciences Food and Beverage (Pty) Ltd
+27 72 333 2148
email us here